IsoPlexis to Participate in the Morgan Stanley Global Healthcare Conference
IsoPlexis Corporation (Nasdaq: ISO) announced participation in the Morgan Stanley Global Healthcare Conference on September 12, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IsoPlexis Corporation (Nasdaq: ISO) announced participation in the Morgan Stanley Global Healthcare Conference on September 12, 2022. The management will engage in a fireside chat at 4:50 p.m. ET, which will also be available as a live and archived webcast on the company’s website. IsoPlexis aims to empower labs by enhancing the understanding of multi-functional immune cells, aiding in the prediction of disease progression and treatment responses. Recognized for its innovative platform, IsoPlexis serves top pharmaceutical firms and leading cancer centers globally.
Details
News Market Reaction – ISO
The recorded move for ISO in the trading session of this news was +0.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRANFORD, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
IsoPlexis’ management is scheduled to participate in a fireside chat on Monday, September 12th at 4:50 p.m. Eastern Time / 1:50 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.isoplexis.com.
About IsoPlexis
IsoPlexis is empowering labs, changing the course of human health.
By leading the discovery and identification of how multi-functional immune cells communicate and respond, IsoPlexis assists researchers in understanding and predicting disease progression, treatment resistance and therapeutic efficacy.
IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.